Notelovitz M, Kitchens C S, Ware M D
Obstet Gynecol. 1984 May;63(5):621-5.
The short-term effects of different types and doses of estrogen therapy on coagulation and fibrinolysis were studied in 35 surgically menopausal women. Dynamic tests of the coagulation cascade, tests indicative of ongoing, intravascular coagulation, and assessments of coagulation inhibition and fibrinolysis were performed. No clinically abnormal responses were found with the tested regimens--1 and 2 mg of 17 beta-estradiol and 0.625 and 1.25 mg of conjugated equine estrogens. Increased plasminogen antigen and activity were found with the conjugated estrogens but not with the 17 beta-estradiol preparations. The age of the woman had no effect on either the direction or magnitude of response to treatment. Estrogen therapy at the reported doses does not appear to adversely affect the coagulation-fibrinolysis systems of surgically menopausal women. Based on their ability to enhance plasminogen activity, conjugated estrogens may be preferred over the 17 beta-estradiol preparations for this clinical population.
对35名手术绝经的女性研究了不同类型和剂量的雌激素疗法对凝血和纤维蛋白溶解的短期影响。进行了凝血级联反应的动态测试、提示正在进行的血管内凝血的测试以及凝血抑制和纤维蛋白溶解的评估。所测试的方案——1毫克和2毫克的17β-雌二醇以及0.625毫克和1.25毫克的结合马雌激素，未发现临床异常反应。结合雌激素可使纤溶酶原抗原和活性增加，但17β-雌二醇制剂则无此作用。女性的年龄对治疗反应的方向或程度均无影响。所报道剂量的雌激素疗法似乎不会对手术绝经女性的凝血-纤维蛋白溶解系统产生不利影响。基于其增强纤溶酶原活性的能力，对于该临床人群，结合雌激素可能优于17β-雌二醇制剂。
